Lead Immune Cell Targeting Program

About Fortitude Biomedicines

Fortitude Biomedicines, founded in 2021 and headquartered in Cambridge, USA, is a biotech startup developing novel antibody-drug conjugates (ADCs) powered by molecular glue degraders. The company's core innovation is the GLUE-DAC™ platform, designed to create therapies with superior potency and a wider therapeutic window for autoimmune and oncology indications. With $13 million in initial financing, Fortitude is advancing a lead immune cell targeting program through IND-enabling studies while building its platform and pipeline. The company operates as a private, pre-revenue entity with a seasoned leadership team experienced in drug discovery and development.

Therapeutic Areas